Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · January 05, 2023

Efficacy and Safety of First-Line Lorlatinib vs Crizotinib in Patients With Advanced ALK-Positive NSCLC

The Lancet Respiratory Medicine


Additional Info

The Lancet Respiratory Medicine
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study
Lancet Respir Med 2022 Dec 16;[EPub Ahead of Print], BJ Solomon, TM Bauer, TSK Mok, G Liu, J Mazieres, F de Marinis, Y Goto, DW Kim, YL Wu, J Jassem, FL López, RA Soo, AT Shaw, A Polli, R Messina, L Iadeluca, F Toffalorio, E Felip

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading